TISSUE ORGANOIDS
Physiologically-tailored tissue organoids are disclosed for monitoring and treating diseases and improving an individual's health.
1 . A physiologically-tailored tissue organoid, comprising:
a plurality of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agent,
wherein when the therapeutic agent is administered to an individual in need thereof, the therapeutic agent improves the individual's health.
2 . The physiologically-tailored tissue organoid of claim 1 , wherein the tissue organoid comprises a stratified skin graft grown from cells taken from an individual.
3 . The physiologically-tailored tissue organoid of claim 1 , wherein the tissue organoid comprises a cultured skin graft grown from embryonic stem cells, human induced pluripotent stem cells, epidermal stem cells, or keratinocytes.
4 - 9 . (canceled)
10 . The physiologically-tailored tissue organoid of claim 1 , wherein the therapeutic agent comprises an enzyme, a protein, a clotting factor, a vitamin, a peptide, a lipid, a toxin, or a combination thereof.
11 . The physiologically-tailored tissue organoid of claim 10 , wherein expression of the therapeutic agent is inducible by an inducer.
12 - 28 . (canceled)
29 . A method of treating an individual in need thereof for a disease, disorder, or addiction, comprising:
contacting a tissue organoid to the individual, the tissue organoid comprising a population of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agents.
30 . The method of claim 29 , wherein the tissue organoid is biointegrated into the individual by grafting or surgical implantation.
31 . The method of claim 29 , wherein the disease or disorder is PKU or hemophilia, and
wherein the addiction is one or more of cocaine addiction, alcoholism, nicotine addiction, or amphetamine addiction.
32 - 49 . (canceled)
50 . The physiologically-tailored tissue organoid of claim 1 , wherein the therapeutic agent comprises phenylalanine ammonia lyase (PAL).
51 . The physiologically-tailored tissue organoid of claim 1 , wherein the therapeutic agent improves the individual's health by treating phenylketonuria (PKU).
52 . The physiologically-tailored tissue organoid of claim 1 , wherein the therapeutic agent comprises Factor VIII or Factor IX.
53 . The physiologically-tailored tissue organoid of claim 52 , wherein the therapeutic agent is conjugated with albumin.
54 . The physiologically-tailored tissue organoid of claim 1 , wherein the therapeutic agent improves the individual's health by treating hemophilia.
55 . The physiologically-tailored tissue organoid of claim 1 , wherein the therapeutic agent comprises hBChE.
56 . The physiologically-tailored tissue organoid of claim 55 , wherein the therapeutic agent improves the individual's health by treating cocaine addiction.
57 . The physiologically-tailored tissue organoid of claim 1 , wherein the therapeutic agent comprises one or more of DkTx, VaTx, glucagon-like peptide 1 (GLP-1), a GLP-1 analog, a modified GLP-1 (mGLP1), and a mGLP1 analog.
58 . The physiologically-tailored tissue organoid of claim 57 , wherein the therapeutic agent is inducible by alcohol consumption by the individual.
59 . The physiologically-tailored tissue organoid of claim 58 , wherein the therapeutic agent improves the individual's health by treating alcoholism.
60 . The physiologically-tailored tissue organoid of claim 1 , wherein the therapeutic agent improves the individual's health by treating nicotine or amphetamine addiction.
61 . A method of treating an individual in need thereof for a disease, disorder, or addiction, comprising:
contacting a tissue organoid to the individual, the tissue organoid comprising a population of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agent, wherein expression of the therapeutic agent is inducible by an inducer; and administering an inducer to the individual to induce expression of the therapeutic agent.